SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY ARTICLE M impact

Cue Biopharma reports positive Phase 2 topline results for CUE-221

Cue Biopharma said CUE-221 met dose-responsive primary and secondary endpoints in chronic spontaneous urticaria, with a favorable safety profile and durable benefit versus placebo and omalizumab.

CUE
SquawkNews Desk

Cue Biopharma announced positive Phase 2 topline results for CUE-221 in chronic spontaneous urticaria, showing dose—responsive primary and secondary endpoints and a favorable safety profile.Key Highlights:Original SEC Filing: Cue Biopharma, Inc. [ CUE ] - 8-K - Sep. 21, 2026This is an AI-powered su…

Related stories

Japan’s Nikkei rises for a third day Japan’s Nikkei rose for a third day. The headline attributes the move to data and earnings fueling AI optimism. M impact | EQUITY | Nov 11, 2026, 02:51 AM UTC Inzisoft to Acquire KRW 2 Billion of Its Own Shares M impact | EQUITY | Nov 11, 2026, 02:43 AM UTC SoftBank Shares Fall 4% After Quarterly Loss SoftBank swung to its first quarterly loss in nearly two years, partly due to $3.7 billion in charges tied to power-generation equipment for U.S. data-center projects. Shares fell M impact | EQUITY | Nov 11, 2026, 02:37 AM UTC UBS Sees Kalyan Jewellers at ₹900 After Q2 Results UBS maintained its view after Kalyan Jewellers reported strong September-quarter results and management pointed to healthy festive demand. Net profit rose sharply, aided by an exce M impact | EQUITY | Nov 11, 2026, 02:36 AM UTC South Korea’s Kospi Extends Gains, Up 1.2% at 5299.65 M impact | EQUITY | Nov 11, 2026, 02:36 AM UTC Asian session market picture: S&P 500 +0.48%, Nasdaq 100 +0.97%; USD/JPY +0.08%, WTI +0.57%, 9984 leads volume Asian session market picture. US index futures: S and P futures is up 0.48 percent, Nasdaq futures is up 0.97 percent, Dow futures is up 0.24 percent and Russell futures is up 0.25 M impact | EQUITY | Nov 11, 2026, 02:30 AM UTC